Targeted nanodelivery in T1D

T1D 中的靶向纳米递送

基本信息

  • 批准号:
    10202270
  • 负责人:
  • 金额:
    $ 57.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-06 至 2021-07-31
  • 项目状态:
    已结题

项目摘要

With no effective therapy to date, the ongoing Type 1 diabetes (T1D) epidemic continues to be a major health problem. While immune therapeutics (ITs) hold great promise for the treatment of T1D, their inadequacy, serious toxicity, side effects, and morbidity have limited research efforts in the lifelong immunosuppression approach. This shortcoming has prompted investigators to search for alternative approaches. Targeted nanomedicine using polymeric nanoparticles (NPs) holds particular promise to enhance the delivery of ITs to treat T1D. This strategy can minimize the undesirable side effects of ITs by delivering them to diseased tissues, where they can undergo sustained release. In this multidisciplinary project, we aim to develop an innovative, targeted nanodelivery method for ITs for T1D. Although progress has been made in developing new formulations, a method of targeted delivery of NPs to specific tissue sites following systemic administration remains to be developed. The priming and activation of autoreactive T cells occurs in the pancreatic lymph nodes (PLNs), where naive T cells enter through lymph node (LN)-restricted vasculature known as high endothelial venules (HEVs) and encounter autoantigens from the pancreas presented by dendritic cells. Activated T cells traffic subsequently to the pancreas, causing insulitis and autoimmune diabetes. Notably, we have found that HEVs are also formed in the pancreas during the onset of diabetes in NOD mice. Our biodegradable polymeric NPs are coated with MECA79 IgM antibody by using maleimide-thiol chemistry (MECA79-MT-NP); MECA79 binds to peripheral node addressin (PNAd), a glycoprotein family expressed only by endothelial cells of the HEV. Here, we demonstrate for the first time the targeted delivery of MECA79-MT-NPs to the PLNs and pancreata of NOD mice following intravenous administration. We also provide human data that supports the clinical applicability of our delivery platform. Active targeted delivery to these sites has never been achieved in T1D. Moreover, our preliminary data shows that encapsulation of the IT anti-CD3 antibody inside our MECA79-MT-NPs results in more effective reversal of autoimmune diabetes in NOD mice than treatment with free anti-CD3. Our main hypothesis is that targeted delivery of anti-CD3 to the pancreatic lymph nodes (PLNs) and pancreata will increase its efficacy and decrease toxicity by reducing systemic dosing significantly. In Aim 1, we will examine and optimize the stability, binding efficacy, and biodistribution of MECA79-conjugated NPs (MECA79-NPs) by utilizing alkyne-azide chemistry to permit the attachment of the pentameric form of MECA79 to the NP (MECA79-AA-NP). In Aim 2, we will assess the clinical efficacy of encapsulating anti-CD3 inside the formulation of MECA79-NP with the optimized properties from Aim 1 in the reversal of autoimmune diabetes in NOD mice as well as elucidate the mechanisms by which our targeted therapy works. In Aim 3, we plan to test the binding capacity to the PLNs and pancreata of human T1D patients of our optimized MECA79-NPs. This multidisciplinary, collaborative approach will lay the groundwork for the introduction of an innovative, targeted delivery method of ITs for T1D.
由于迄今为止没有有效的治疗方法,持续的1型糖尿病(T1D)流行仍然是一个主要的健康问题

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Reza Abdi其他文献

Reza Abdi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Reza Abdi', 18)}}的其他基金

Targeted immune therapies in heart transplantation
心脏移植中的靶向免疫治疗
  • 批准号:
    10573846
  • 财政年份:
    2023
  • 资助金额:
    $ 57.09万
  • 项目类别:
The novel role of beta3 integrin in regulating alloimmunity
β3整合素在调节同种免疫中的新作用
  • 批准号:
    10573306
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
The novel role of beta3 integrin in regulating alloimmunity
β3整合素在调节同种免疫中的新作用
  • 批准号:
    10467425
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
New way in delivering immunomodulatory drugs in T1D
在 T1D 中提供免疫调节药物的新方法
  • 批准号:
    10576373
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
New way in delivering immunomodulatory drugs in T1D
在 T1D 中提供免疫调节药物的新方法
  • 批准号:
    10457732
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
Lymph Node Delivery in Transplantation
移植中的淋巴结输送
  • 批准号:
    10650172
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
IRI, innate immunity and transplant rejection
IRI、先天免疫和移植排斥
  • 批准号:
    10576902
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
IRI, innate immunity and transplant rejection
IRI、先天免疫和移植排斥
  • 批准号:
    10371989
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
Lymph nodes at the crossroads of allo immunity and regulation
淋巴结处于同种异体免疫和调节的十字路口
  • 批准号:
    10662304
  • 财政年份:
    2020
  • 资助金额:
    $ 57.09万
  • 项目类别:
HVEM pathway regulating FRC function and transplant tolerance
HVEM 通路调节 FRC 功能和移植耐受
  • 批准号:
    10662313
  • 财政年份:
    2020
  • 资助金额:
    $ 57.09万
  • 项目类别:

相似海外基金

Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
  • 批准号:
    573824-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
    University Undergraduate Student Research Awards
Exploring the missing reactivity of heteroatom-substituted alkynes
探索杂原子取代的炔烃缺失的反应性
  • 批准号:
    559671-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
LEAPS-MPS: Developing a Spectroscopic Map for Terminal Alkynes
LEAPS-MPS:开发末端炔烃的光谱图
  • 批准号:
    2213339
  • 财政年份:
    2022
  • 资助金额:
    $ 57.09万
  • 项目类别:
    Standard Grant
Development of Synthetic Methods for Hetero-fused pi-Conjugated Compounds Based on Trans-Addition to Alkynes
基于炔烃反式加成的异稠合π共轭化合物的合成方法研究进展
  • 批准号:
    21K05061
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Enantioselective Carboalumination of Alkenes and Alkynes Catalyzed by Rare-Erath Metal Catalysts
稀土金属催化剂催化烯烃和炔烃对映选择性碳铝化反应的研究进展
  • 批准号:
    21F21334
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10544730
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10320911
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
Development of beta-carbon elimination reactions of alkynes from unstrained vinyl complexes
无应变乙烯基配合物中炔烃的β-碳消除反应的进展
  • 批准号:
    21K05101
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
  • 批准号:
    563146-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
    University Undergraduate Student Research Awards
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10581995
  • 财政年份:
    2021
  • 资助金额:
    $ 57.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了